Roche's obesity drug shows up to 10.7% weight loss in mid-stage trial

Core Insights - Roche's experimental obesity drug, petrelintide, demonstrated a weight loss of up to 10.7% in a mid-stage trial involving 493 patients over 42 weeks, significantly outperforming the placebo group, which showed only a 1.7% weight loss [1]. Company Overview - Roche, through its subsidiary Genentech, acquired petrelintide via a collaboration and licensing agreement with Zealand Pharma, granting Roche shared development rights to this amylin-based obesity therapy [1].